Andrzej Jakubowiak to Drug Therapy, Combination
This is a "connection" page, showing publications Andrzej Jakubowiak has written about Drug Therapy, Combination.
Connection Strength
0.101
-
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 01 11; 395(10218):132-141.
Score: 0.038
-
Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):97-111.
Score: 0.025
-
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
Score: 0.021
-
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.
Score: 0.017